What oral GLP-1 actually means in 2026 Until recently, every GLP-1 receptor agonist used for weight loss was an injection
However, their use raises important clinical considerations
Six independent layers of clinical, regulatory, and security infrastructure stand behind every test, protocol, and recommendation
Sudden discontinuation can lead to rapid weight regain and potential metabolic disturbances, which can undermine the progress made during treatment
This study was limited in scope: Conducted on 24 rats, not humans Administered a single dose Designed only to demonstrate that some absorption is possible Importantly, the study itself includes this disclaimer: This proof-of-concept study is not intended to provide guidance on the sublingual dosing of semaglutide in humans, or dosing conversion from other forms to sublingual administration. This means the only research behind these products cannot confirm whether they work in humans or provide guidance on appropriate dosing
It's a verification framework